GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Logo

GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş.

Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.

GENIL | IS

Overview

Corporate Details

ISIN(s):
TREGENL00016 (+1 more)
LEI:
789000A4NW6W4D8Z4H25
Country:
Türkiye
Address:
MUSTAFA KEMAL MAH. 2119. SOK. NO;3 D:2-3 ÇANKAYA/ANKARA, 06520 ANKARA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Established in 1998, GEN İlaç ve Sağlık Ürünleri is a pharmaceutical company focused on providing global solutions for rare diseases and unmet health needs. The company leverages over 25 years of experience through a versatile business model that includes strategic partnerships with global firms and in-house development. It operates its own GMP-certified production facility and R&D center to create and manufacture competitive products for international markets. GEN specializes in treatments within key therapeutic areas such as neurology, endocrinology, nephrology, oncology, and hematology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 14:39
Environmental & Social Information
Update About Solar Power Plant Project
Turkish 20.7 KB
2025-09-09 17:10
Transaction in Own Shares
Notification Regarding Share Buy-Back
English 7.6 KB
2025-08-28 17:19
Regulatory News Service
Disclosure of Credit Rating Score
Turkish 230.2 KB
2025-08-28 17:19
Capital/Financing Update
Disclosure of Credit Rating Score
Turkish 19.2 KB
2025-08-20 08:37
Related Party Transaction
Tender Result Notified by the Organization which Authorized by Our Company
Turkish 18.9 KB
2025-08-18 17:10
Environmental & Social Information
Participation Finance Principles Information Form
English 53.0 KB
2025-08-13 19:52
Regulatory News Service
01.01.2025 - 30.06.2025 period activity report
Turkish 554.5 KB
2025-08-13 19:52
Regulatory News Service
01.01.2025 - 30.06.2025 period activity report
Turkish 2.1 MB
2025-08-13 19:52
Report Publication Announcement
01.01.2025 - 30.06.2025 period activity report
English 11.1 KB
2025-08-13 19:37
Regulatory News Service
Financial Report
Turkish 2.3 MB
2025-08-13 19:37
Interim Report
Financial Report
English 2.6 MB
2025-08-13 19:37
Interim Report
01.01.2025 - 30.06.2025 Dönemi Sorumluluk Beyanı
Turkish 20.0 KB
2025-08-13 08:49
Regulatory News Service
Signature of New Distribution Agreement
Turkish 20.6 KB
2025-08-13 08:27
Share Issue/Capital Change
Correction of disclosure 11/08/2025
English 13.8 KB
2025-08-11 20:41
Regulatory News Service
Support of Two Innovative R&D project within the framework of Technology Orient…
Turkish 18.3 KB

Automate Your Workflow. Get a real-time feed of all GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.